<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312517</url>
  </required_header>
  <id_info>
    <org_study_id>MISP 57338</org_study_id>
    <nct_id>NCT03312517</nct_id>
  </id_info>
  <brief_title>Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs</brief_title>
  <official_title>A Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (Responsivity) of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold
      Effects (responsivity) of Belsomra 10 mg and 20 mg to Placebo in non-elderly Insomniacs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an interventional single site study using a double blind, randomized 3-way
      crossover design with Belsomra 10 mg and 20 mg compared to a placebo. The total number of
      enrolled patients proposed is 12. A cross-over design is utilized so participants will be
      exposed to all treatment conditions in a controlled order (Belsomra 10 mg, 20 mg and
      placebo). Both men and women with insomnia will be utilized as the study population to
      improve the generalizability of outcome data. Subjects with other sleep disorders or unstable
      medical/psychiatric disorders will be excluded from the trial. Inclusion criteria will be men
      and women &gt;18 and &lt; 65 years of age.

      Subjects will be randomly assigned to treatment sequences using a Latin square design. After
      a subject has qualified for the study, the next sequentially available randomization number
      will be assigned. The subject will be administered study drug corresponding with this
      assigned number.

      During the night of each respective Polysomnography (PSG) assessments, subjects will be
      awoken at the approximate T-max of the active drug (2.5 hrs), with a matching placebo
      condition at the same time point using an identical responsivity protocol for each condition.
      The rationale for this is that t-max represents the time of greatest potential risk for a
      hypnotic in terms of balance, responsivity, and memory. Responsivity will be assessed using
      the Auditory Awakening Threshold test (AAT) and will be measured at 2.5 hours post dose for
      the Belsomra 10 and 20 mg (BEL), and placebo (PBO) conditions. Responsivity will be assessed
      at the approximate time above immediately after 5 minutes of consolidated (without arousals)
      NREM ( Non- rapid eye movement) stage 2 sleep has occurred.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Actual">October 25, 2018</completion_date>
  <primary_completion_date type="Actual">October 25, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>double-blind, randomized 3-way crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Study is double blinded. Investigator, participant, or care provider will be blinded to watch drug the subject receives during each treatment week.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Auditory Awakening Threshold</measure>
    <time_frame>2.5 hours post-dose of each Study Drug administration</time_frame>
    <description>Subjects will be awakened during the night to auditory awakening tones.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Suvorexant 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suvorexant 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant 10 mg</intervention_name>
    <description>Subject will receive suvorexant 10mg</description>
    <arm_group_label>Suvorexant 10mg</arm_group_label>
    <other_name>belsomra 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant 20 mg</intervention_name>
    <description>Subject will receive suvorexant 20mg</description>
    <arm_group_label>Suvorexant 20mg</arm_group_label>
    <other_name>Belsomra 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Subject will receive placebo.</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Meets DSM-5 ( Diagnostic and statistical manual) diagnostic criteria for insomnia
             disorder

          -  ISI ( Insomnia Severity Index) &gt; 10

          -  Age &gt;18 and &lt; 65

          -  Negative audiological screening exam

        Exclusion Criteria:

          -  BMI &gt;35 kg/m2

          -  Have symptoms consistent with the diagnosis of any sleep disorder other than insomnia
             (e.g., sleep apnea, narcolepsy, periodic leg movements, or restless leg syndrome).

          -  Have a known or suspected diagnosis of Acquired Immune Deficiency Syndrome (AIDS), or
             have tested seropositive for human immunodeficiency virus (HIV) antibody or antigen
             previously.

          -  Have any clinically significant abnormal finding in physical examination, neurological
             assessment, vital signs, elevated body temperature, or clinical laboratory tests, as
             determined by the Investigator.

          -  Have a known or exaggerated pharmacological sensitivity, hypersensitivity, or
             intolerance to Belsomra.

          -  Currently taking CYP3A inhibitors.

          -  Positive breathalyzer test for alcohol at Screening, PSG Screening or any Treatment
             night, or a positive urine drug screen (for amphetamines, barbiturates,
             benzodiazepines, cocaine, opiates, or cannabinoids) at Screening;

          -  History of hearing difficulty (e.g., use of a hearing aid).

          -  Intends to use any medication including over-the-counter (OTC) medications that would
             interfere with normal sleep architecture (such as systemic steroids, beta-adrenergic
             blockers, amphetamines, modafinil, etc.);

          -  Self-reports use of products containing nicotine of greater than 15 cigarettes daily,
             or cannot avoid products containing nicotine during the normal sleep periods;

          -  Self report consumption of more than five alcoholic beverages on any one day or &gt; 14
             alcoholic beverages weekly over the past week;

          -  Have a history of epilepsy or serious head injury

          -  Average Time in Bed &lt; 6.5 hrs.

          -  Have used prescribed or OTC medications within 7 days of screening (Day 0) or intend
             to use any prescription or OTC medication during the study that may interfere with the
             evaluation of the study drug. This restriction includes taking medications that affect
             the Central nervous system. Any chronic maintenance therapy should have been
             maintained at a stable dosing regimen for at least 30 days before screening and
             subjects must continue this regimen throughout the study.

          -  Have used an investigational drug within 30 days or five half lives (whichever is
             longer) before screening, or plans to use an investigational drug during the study or
             have used belsomra or zolpidem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris L Drake, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Medical Center - Columbus</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Greenblatt DJ, Harmatz JS, Shader RI. Update on Psychotropic Drug Prescribing in the United States: 2014-2015. J Clin Psychopharmacol. 2018 Feb;38(1):1-4. doi: 10.1097/JCP.0000000000000831.</citation>
    <PMID>29215384</PMID>
  </reference>
  <reference>
    <citation>Bonnet MH, Webb WB, Barnard G. Effect of flurazepam, pentobarbital, and caffeine on arousal threshold. Sleep. 1979 Spring;1(3):271-9.</citation>
    <PMID>504872</PMID>
  </reference>
  <reference>
    <citation>Johnson LC, Church MW, Seales DM, Rossiter VS. Auditory arousal thresholds of good sleepers and poor sleepers with and without flurazepam. Sleep. 1979 Spring;1(3):259-70.</citation>
    <PMID>228373</PMID>
  </reference>
  <reference>
    <citation>Johnson LC, Spinweber CL, Webb SC, Muzet AG. Dose level effects of triazolam on sleep and response to a smoke detector alarm. Psychopharmacology (Berl). 1987;91(4):397-402.</citation>
    <PMID>3108921</PMID>
  </reference>
  <reference>
    <citation>Drake CL, Durrence H, Cheng P, Roth T, Pillai V, Peterson EL, Singh M, Tran KM. Arousability and Fall Risk During Forced Awakenings From Nocturnal Sleep Among Healthy Males Following Administration of Zolpidem 10 mg and Doxepin 6 mg: A Randomized, Placebo-Controlled, Four-Way Crossover Trial. Sleep. 2017 Jul 1;40(7). doi: 10.1093/sleep/zsx086.</citation>
    <PMID>28575467</PMID>
  </reference>
  <reference>
    <citation>Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep. 2012 Aug 1;35(8):1097-104. doi: 10.5665/sleep.1996.</citation>
    <PMID>22851805</PMID>
  </reference>
  <reference>
    <citation>Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28.</citation>
    <PMID>23197752</PMID>
  </reference>
  <reference>
    <citation>Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 May;13(5):461-71. doi: 10.1016/S1474-4422(14)70053-5. Epub 2014 Mar 27.</citation>
    <PMID>24680372</PMID>
  </reference>
  <reference>
    <citation>Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci. 2014 May 16;8:182. doi: 10.3389/fnbeh.2014.00182. eCollection 2014.</citation>
    <PMID>24904334</PMID>
  </reference>
  <reference>
    <citation>Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep. 2016 Mar 1;39(3):603-12. doi: 10.5665/sleep.5536.</citation>
    <PMID>26943466</PMID>
  </reference>
  <reference>
    <citation>Manber R, Harvey A. Historical perspective and future directions in Cognitive Behavioral Therapy for insomnia and behavioral sleep medicine. Clin Psychol Rev. 2005 Jul;25(5):535-8.</citation>
    <PMID>15950345</PMID>
  </reference>
  <reference>
    <citation>Allen RP, Burchell BJ, MacDonald B, Hening WA, Earley CJ. Validation of the self-completed Cambridge-Hopkins questionnaire (CH-RLSq) for ascertainment of restless legs syndrome (RLS) in a population survey. Sleep Med. 2009 Dec;10(10):1097-100. doi: 10.1016/j.sleep.2008.10.007. Epub 2009 Feb 4.</citation>
    <PMID>19195928</PMID>
  </reference>
  <reference>
    <citation>Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A, Shapiro CM. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008 May;108(5):812-21. doi: 10.1097/ALN.0b013e31816d83e4.</citation>
    <PMID>18431116</PMID>
  </reference>
  <reference>
    <citation>Bastien CH, Valli√®res A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307.</citation>
    <PMID>11438246</PMID>
  </reference>
  <reference>
    <citation>Keefe FB, Johnson LC, Hunter EJ. EEG and autonomic response pattern during waking and sleep stages. Psychophysiology. 1971 Mar;8(2):198-212.</citation>
    <PMID>4326132</PMID>
  </reference>
  <reference>
    <citation>Spinweber CL, Johnson LC. Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold. Psychopharmacology (Berl). 1982;76(1):5-12.</citation>
    <PMID>6123129</PMID>
  </reference>
  <reference>
    <citation>Bruck D, Thomas IR. Smoke alarms for sleeping adults who are hard-of-hearing: comparison of auditory, visual, and tactile signals. Ear Hear. 2009 Feb;30(1):73-80. doi: 10.1097/AUD.0b013e3181906f89.</citation>
    <PMID>19125029</PMID>
  </reference>
  <reference>
    <citation>Rosenthal L, Bishop C, Helmus T, Krstevska S, Roehrs T, Roth T. Auditory awakening thresholds in sleepy and alert individuals. Sleep. 1996 May;19(4):290-5.</citation>
    <PMID>8776786</PMID>
  </reference>
  <reference>
    <citation>Busby KA, Mercier L, Pivik RT. Ontogenetic variations in auditory arousal threshold during sleep. Psychophysiology. 1994 Mar;31(2):182-8.</citation>
    <PMID>8153254</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <results_first_submitted>September 18, 2019</results_first_submitted>
  <results_first_submitted_qc>October 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2019</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Christopher Drake</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>belsomra</keyword>
  <keyword>suvorexant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03312517/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03312517/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Presence of insomnia determined by clinical interview performed by a physician board certified in sleep medicine</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Suvorexant 10mg, Then Suvorexant 20mg</title>
          <description>Subjects first received Placebo, then Suvorexant 10mg, then Suvorexant 20mg. Treatment was administered 30 min. before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Suvorexant 20mg, Then Suvorexant 10mg</title>
          <description>Subjects first received Placebo, then Suvorexant 20mg, then Suvorexant 10mg. Treatment was administered 30 min. before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
        </group>
        <group group_id="P3">
          <title>Suvorexant 10, Then Placebo, Then Suvorexant 20</title>
          <description>Subjects first received Suvorexant 10mg, then placebo, then Suvorexant 20mg. Treatment was administered 30 min. before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
        </group>
        <group group_id="P4">
          <title>Suvorexant 10mg, Then Suvorexant 20mg, Then Placebo</title>
          <description>Subjects first received Suvorexant 10mg, then Suvorexant 20mg, then placebo. Treatment was administered 30 min. before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
        </group>
        <group group_id="P5">
          <title>Suvorexant 20mg, Placebo, Suvorexant 10mg</title>
          <description>Subjects first received Suvorexant 20mg, placebo, then Suvorexant 10mg. Treatment was administered 30 min. before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
        </group>
        <group group_id="P6">
          <title>Suvorexant 20, Suvorexant 10mg, Placebo</title>
          <description>Subjects first received Suvorexant 20, then Suvorexant 10mg, then Placebo. Treatment was administered 30 min. before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Analyzed Sample</title>
          <description>Crossover study, all subjects will receive belsomra 10mg, belsomra 20mg and placebo before bedtime in 3 separate overnights. In the middle of the night, subjects will be awakened to auditory awakening tones.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants in analysis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Auditory Awakening Threshold</title>
        <description>Subjects will be awakened during the night to auditory awakening tones.</description>
        <time_frame>2.5 hours post-dose of each Study Drug administration</time_frame>
        <population>We compared the odds of individuals sleeping through a 85-db stimulus in each condition. A generalized linear mixed model was used to estimate binary outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant 10mg</title>
            <description>Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
Suvorexant 10 mg: Subject will receive suvorexant 10mg</description>
          </group>
          <group group_id="O2">
            <title>Suvorexant 20mg</title>
            <description>Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
Suvorexant 20 mg: Subject will receive suvorexant 20mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo Oral Capsule</title>
            <description>Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
Placebo oral capsule: Subject will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Auditory Awakening Threshold</title>
          <description>Subjects will be awakened during the night to auditory awakening tones.</description>
          <population>We compared the odds of individuals sleeping through a 85-db stimulus in each condition. A generalized linear mixed model was used to estimate binary outcomes</population>
          <units>decibels (db)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.17" spread="23.44"/>
                    <measurement group_id="O2" value="83.75" spread="20.24"/>
                    <measurement group_id="O3" value="79.17" spread="22.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Adverse Event were collected before and after every overnight. In addition, a Safety Follow-up 2 weeks after either study completion or study withdrawal was performed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>All 12 subjects received placebo, 30 min before bedtime in one of the treatment nights. Order of treatment was assigned randomly. In the middle of the night, subjects were awakened to auditory awakening tones.</description>
        </group>
        <group group_id="E2">
          <title>Belsomra 20mg</title>
          <description>All 12 subjects received belsomra 20mg, 30 min before bedtime in one of the treatment nights. Order of treatment was assigned randomly. In the middle of the night, subjects were awakened to auditory awakening tones.</description>
        </group>
        <group group_id="E3">
          <title>Belsomra 10mg</title>
          <description>All 12 subjects received belsomra 10mg, 30 min before bedtime in one of the treatment nights. Order of treatment was assigned randomly. In the middle of the night, subjects were awakened to auditory awakening tones.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tingling sensation in arm</sub_title>
                <counts group_id="E1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upset</sub_title>
                <counts group_id="E1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Drake, PhD</name_or_title>
      <organization>Henry Ford Sleep Research Center</organization>
      <phone>248-344-6672</phone>
      <email>cdrake1@hfhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

